Clinical Trial Update: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on a phase 2/3 study comparing Zanzalintinib (XL092) plus pembrolizumab to pembrolizumab alone in PD-L1-positive recurrent/metastatic head…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Zanzalintinib (XL092) (Zanzalintinib)

Snippet

Sponsor: Exelixis | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING